Skip Navigation LinksHome > March 2010 - Volume 53 - Issue 1 > The Use of Recombinant Activated FVII in Postpartum Hemorrha...
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e3181cc4378
Postpartum Hemorrhage

The Use of Recombinant Activated FVII in Postpartum Hemorrhage

FRANCHINI, MASSIMO MD*; FRANCHI, MASSIMO MD, PhD; BERGAMINI, VALENTINO MD; MONTAGNANA, MARTINA MD; SALVAGNO, GIAN LUCA MD; TARGHER, GIOVANNI MD§; LIPPI, GIUSEPPE MD

Collapse Box

Abstract

Severe bleeding remains a leading cause of morbidity and mortality in obstetrics. The first-line standard treatment of massive postpartum hemorrhage (PPH) includes medical measures directed at improving uterine tone, replacement of lost intravascular volume, blood and coagulation factors, and surgical or invasive procedures. Recently, a number of case reports or case series have reported the successful “off-label” use of recombinant activated factor VII (rFVIIa) in PPH unresponsive to conventional treatments. In this review, a critical analysis of the published literature on the use of rFVIIa in severe PPH was performed. Overall, a total of 272 PPH women were collected among the largest case series and/or international registries. No randomized controlled trials have been conducted in this area. Currently, the literature data suggest that, at a median dose of 81.5 μg/kg, rFVIIa is effective in stopping or reducing bleeding in 85% of the cases. Finally, on the basis of the evidence from the literature and on own experience, we included some recommendations and an algorithm on the therapeutic role of rFVIIa in the management of PPH.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Readers Of this Article Also Read